• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Rice Yehuda Michael

    1/26/24 11:02:17 AM ET
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBLT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    RICE YEHUDA MICHAEL

    (Last) (First) (Middle)
    C/O NOTABLE LABS, LTD.
    320 HATCH DRIVE

    (Street)
    FOSTER CITY CA 94404

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Notable Labs, Ltd. [ NTBL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/24/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $1.28 01/24/2024 A 6,534 (1) 01/24/2034 Ordinary Shares 6,534 $0 6,534 D
    Explanation of Responses:
    1. Option vests 50% on the first anniversary of date of grant and thereafter in four equal quarterly installments ending on the second anniversary of the date of grant.
    /s/ Yehuda Michael Rice 01/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VBLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VBLT

    DatePrice TargetRatingAnalyst
    7/20/2022Outperform → Perform
    Oppenheimer
    7/20/2022Buy → Neutral
    H.C. Wainwright
    7/18/2022$5.50Outperform
    Oppenheimer
    4/28/2022$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $VBLT
    Financials

    Live finance-specific insights

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

      Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

      2/23/23 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

      5/17/22 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Feinberg Peter

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:45 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Patsi Tuomo

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:20 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Galen Michele

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:04:43 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Leadership Updates

    Live Leadership Updates

    See more

    $VBLT
    SEC Filings

    See more

    $VBLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance
    • VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

      CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Comm

      1/18/22 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

      TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will cont

      10/5/21 8:00:00 AM ET
      $NBSE
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Vascular Biogenics Ltd.

      DEF 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/16/24 9:00:13 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Vascular Biogenics Ltd.

      PRE 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/5/24 5:00:08 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics Ltd. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      2/2/24 4:05:36 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by Oppenheimer

      Oppenheimer downgraded Vascular Biogenics from Outperform to Perform

      7/20/22 9:01:50 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Vascular Biogenics from Buy to Neutral

      7/20/22 7:39:29 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Vascular Biogenics with a new price target

      Oppenheimer resumed coverage of Vascular Biogenics with a rating of Outperform and set a new price target of $5.50

      7/18/22 9:22:46 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vascular Biogenics Ltd. (Amendment)

      SC 13G/A - Notable Labs, Ltd. (0001603207) (Subject)

      1/11/24 5:22:04 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Vascular Biogenics Ltd.

      SC 13D - Notable Labs, Ltd. (0001603207) (Subject)

      10/19/23 1:34:02 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vascular Biogenics Ltd.

      SC 13G - Vascular Biogenics Ltd. (0001603207) (Subject)

      2/1/22 4:20:25 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

      Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted t

      10/12/23 9:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

      MODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable Labs ("Notable") at the annual and special meeting (the "Meeting") for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number of ordinary shares, nominal value of NIS 0.01 ("VBL Ordinary Shares") held, are encouraged to vote "FOR" the Merger and related proposals described in the definitive proxy statement/prospectus/information statement previously filed by VBL with the U.S. Securities and Exchange Commission (the "SEC") in connection with

      10/4/23 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care